Yale Medicine School: New Class of Oncogenic Fusions Revealed in Lung and Pancreatic Cancer
March 16, 2022
March 16, 2022
NEW HAVEN, Connecticut, March 16 (TNSJou) -- Yale School of Medicine issued the following news:
A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development. The research is described online ahead of print in Clinical Cancer Research.
The research team studied 103 lung adenocarcinomas i . . .
A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development. The research is described online ahead of print in Clinical Cancer Research.
The research team studied 103 lung adenocarcinomas i . . .